tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Bausch + Lomb Confirms Efficacy of LUMIFY Preservative Free Eye Drops

Story Highlights
Bausch + Lomb Confirms Efficacy of LUMIFY Preservative Free Eye Drops

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Bausch + Lomb Corporation ( (BLCO) ) has provided an update.

Bausch + Lomb Corporation announced the publication of Phase 3 data confirming that its LUMIFY Preservative Free redness reliever eye drops are as safe and effective as the original LUMIFY. The study, involving 380 participants, demonstrated that the preservative-free version is non-inferior in efficacy and has a favorable safety profile, providing an effective option for individuals with sensitive eyes. The results reinforce LUMIFY’s position as the leading doctor-recommended redness reliever brand, offering a well-tolerated alternative for consumers with ocular redness who have sensitivities to preservatives.

The most recent analyst rating on (BLCO) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.

Spark’s Take on BLCO Stock

According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.

Bausch + Lomb’s stock score is primarily influenced by its financial performance and technical analysis. While the company shows strong market positioning and growth in key segments, profitability and cash flow issues weigh heavily. Technical indicators are favorable, but nearing overbought levels. The valuation remains weak, primarily due to negative earnings. However, recent corporate events and resilient earnings call outcomes provide some positive outlook.

To see Spark’s full report on BLCO stock, click here.

More about Bausch + Lomb Corporation

Bausch + Lomb is a global leader in eye health, offering a comprehensive portfolio of approximately 400 products, including contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products, and ophthalmic surgical devices. With a significant global presence, the company is headquartered in Vaughan, Ontario, and has corporate offices in Bridgewater, New Jersey.

Average Trading Volume: 869,852

Technical Sentiment Signal: Hold

Current Market Cap: $5.1B

Learn more about BLCO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1